The gene-editing tool’s potential to upend science is dizzying.
Read more
Category: biotech/medical – Page 2,706
More progress with cancer using a senolytic compound found in Indian Long Peppers.
DALLAS – January 3, 2017 – UT Southwestern Medical Center scientists have uncovered the chemical process behind anti-cancer properties of a spicy Indian pepper plant called the long pepper, whose suspected medicinal properties date back thousands of years.
Read more
Luv this.
Proteins are the workhorse molecules of life. Among their many jobs, they carry oxygen, build tissue, copy DNA for the next generation, and coordinate events within and between cells. Now scientists at the University of North Carolina at Chapel Hill have developed a method to control proteins inside live cells with the flick of a switch, giving researchers an unprecedented tool for pinpointing the causes of disease using the simplest of tools: light.
The work, led by Klaus Hahn and Nikolay Dokholyan and spearheaded by Onur Dagliyan, a graduate student in their labs, builds on the breakthrough technology known as optogenetics. The technique, developed in the early 2000s, allowed scientists, for the first time, to use light to activate and deactivate proteins that could turn brain cells on and off, refining ideas of what individual brain circuits do and how they relate to different aspects of behavior and personality.
Multiplexed optogenetic control, using Photo-inhibitable Vav2 (PA-Vav2) and Photo-inhibitable Rac1 (PI-Rac1) in the same cell.
Read more
Samuel Sia, a professor of biomedical engineering at New York City’s Columbia University, has developed a 3D printed biobot that can be implanted in the body to release controlled doses of drugs. The amazing device can be controlled from outside the body using only magnets.
For patients who have been diagnosed with cancer, treatment options are often few and far between, and in many serious cases, starting an intense course of chemotherapy becomes a necessity rather than a choice. But despite being a powerful weapon against cancer, chemotherapy takes its toll on the body in a number of ways: chronic pain, nausea, fatigue, hair loss, and the chance of infertility are just some of the adverse effects that chemotherapy can present. Fortunately, scientists are working hard to develop more effective ways of delivering chemotherapy drugs, including a new 3D printing method that involves fabricating squishy, “clockwork” micromachines that deliver precise drug doses from within the body.
Read more
Is it possible to kill bacteria with bacteria?
This is the unorthodox question posed by a team of researchers funded by the Defense Advanced Research Projects Agency (DARPA)—a research and development organization within the U.S. Department of Defense—that is exploring whether an unusual type of bacteria that eats other bacteria could be a new weapon in the fight against drug-resistant infections.
Known as the Pathogen Predator program, the DARPA initiative (led by Dr. Barry Pallotta) is part of a growing effort to seek new and innovative ways to defeat drug-resistant superbugs, which are rapidly evolving to beat even our most powerful antibiotics.
Read more
Nice.
Synthetic RNA kit business Synthego has raised $41 million to step up its efforts to make CRISPR gene editing easier and more accurate. The West Coast startup relied heavily on tech VCs for the cash, but also gained validation from having CRISPR pioneer Jennifer Doudna invest in its business.
Redwood City, CA-based Synthego exited stealth in August, four years after it was set up by two former SpaceX computer engineers. In those early years, which were bankrolled by an $8.3 million investment in 2013, Synthego established an automated manufacturing process for guide RNA products that it thinks sets it apart from larger competitors in terms of cost, turnaround time and editing efficiency.
Sythengo has persuaded some big names it is on to something. 8VC, an infrastructure-focused VC that also invested in uBiome, led the round with support from fellow new backers AME Cloud Ventures, Elements Capital, OS Fund, Alexandria Equities and ZhenFund. Existing investors including Peter Thiel’s Founders Fund and Menlo Ventures also contributed to the Series B round.
Read more
Continuous-flow system went from synthesis to dosage forms in hours.
Drug manufacturers typically produce drugs in batches in large factories. But a new trend is developing in the pharmaceutical industry to reduce infrastructure costs by using small continuous-flow systems to make drug doses on demand.
Read more
Let’s show them we appreciate! smile
Removing senescent cells could help reduce age-related diseases and improve health. You have the power to help shape the future of medicine by supporting the CellAge campaign at lifespan.io check it out on the link below:
https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/
Read more
For just $25 your name will be converted into cool DNA coding language and placed in the special CellAge time capsule for a future generation to discover!
Your donation could help us to develop cures for age-related diseases, check out the CellAge project on Lifespan.io today.
https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/
Read more
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, announced the commercial approval of naturally derived Bioquantine food ingredients in the Eurasian Customs Union (formerly known as the Customs Union of Belarus, Kazakhstan, and Russia). Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, collaborated with Bioquark Inc. on the regulatory approvals.
“We are very excited about this successful regulatory approval,” said Ira S. Pastor, CEO, Bioquark Inc. “The commercialization of Bioquantine food ingredients, including functional foods, drinks, and dietary supplements, represents another important step in our continued evolution as a company focused on a broad range of products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome and virome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.
“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival,” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This Eurasian initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
Link to Press — http://www.prweb.com/releases/2017/01/prweb13955162.htm